Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/UMEC/VI single-inhaler triple therapy versus tiotropium in COPD
2017-001190-16Phase 4Completed
- Sponsor
- GSK
- Start
- Mar 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fluticasone, umeclidinium, vilanterol and tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change from baseline in trough FEV1 at Week 12. Started Mar 2018; status: completed.
02
Drugs
fluticasoneumeclidiniumvilanteroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2017-001190-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001190-16.